Compare

FOXO4-DRI vs TB-500 Fragment

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

FOXO4-DRI

28 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 97% · Mixed 3% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
178
Energy
178

Self-reported dose per injection

Median bucket: 2+ mg · Most common: 2+ mg

Reports span 1 to ≥ 2 mg (open-ended top bucket)

1–2 mg
58
2+ mg
120

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 194 days · Based on 26 repeat reporters

TB-500 Fragment

26 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 3% · Mixed 97% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
176

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site irritation
171

Self-reported dose per injection

Median bucket: 2+ mg · Most common: 2+ mg

Reports span 1 to ≥ 2 mg (open-ended top bucket)

1–2 mg
59
2+ mg
117

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 188 days · Based on 24 repeat reporters

Sources (6)

Published sources linked on the FOXO4-DRI and TB-500 Fragment wiki pages.

  1. PubMed

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)

    Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017

    Source
    Wiki study page →
  2. PubMed

    Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

    Born E, Lipskaia L, Breau M, et al. Circulation. 2023

    Source
    Wiki study page →
  3. PubMed

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

    Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017

    Source
    Wiki study page →
  4. PubMed

    Thymosin beta4: a multi-functional regenerative peptide (review)

    Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  5. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  6. PubMed

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026

    Source
    Wiki study page →